Primary Central Nervous System Histiocytic Sarcoma During Neuromyelitis Optica Spectrum Disorder Authors: Naoko Saito-Sato, Yuan Bae, Hideji Hashida Published: 2026 Dear Editor, Histiocytic sarcoma (HS) is a rare hematopoietic malignancy that is seldom found with primary involvement in the central nervous system (CNS).1234 Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disease characterized by anti-aquaporin-4 antibodies (AQP4-Ab). We report an exceedingly rare case of primary-CNS-involvement HS (PCNSHS) occurring during the clinical course of NMOSD. A 64-year-old female with a history of cervicothoracic posterior decompression surgery presented with right lower-limb weakness, paresthesia, and gait disturbance. Her medical history included hypertension, dyslipidemia, and Graves’ disease. A neurological examination showed bilateral lower-limb weakness, sensory disturbances, and upper-limb hyperreflexia. Her Expanded Disability Status Scale (EDSS) score was 7.5. A cerebrospinal fluid (CSF) analysis revealed pleocytosis (39 cells/µL) with 97% mononuclear cells, elevated protein (3.12 g/L), and positive oligoclonal bands. AQP4-Ab were elevated in both serum (14.2 U/mL in an enzyme-linked immunosorbent assay [ELISA], with positivity in a cell-based assay [CBA]) and CSF (4.2 U/mL in ELISA). Spinal T2-weighted MRI revealed extensive hyperintense lesions spanning the thoracic spinal cord, with heterogeneous gadolinium enhancement, which was consistent with longitudinally extensive transverse myelitis (LETM) (Fig. 1A). She was diagnosed with NMOSD. Her symptoms improved after treatment with high-dose intravenous corticosteroids, plasma exchange, and maintenance therapy with azathioprine and prednisolone. She regained the ability to walk and was transferred to a rehabilitation facility. Her EDSS score improved to 3.0. Five months later she developed recurrent bilateral leg pain and progressive weakness and eventually became nonambulatory. A neurological examination revealed incomplete sensory loss below the T8 level. Her EDSS score had worsened to 7.5, but AQP4-Ab were not elevated in serum (below 1.5 U/mL in an ELISA, with negativity in a CBA). CSF collection was difficult due to subarachnoid space narrowing caused by lumbar spinal cord swelling. MRI of the lumbar spine showed marked swelling of the cauda equina with homogeneous gadolinium enhancement on T1-weighted images (Fig. 1B). The LETM lesion present at the time of the initial hospitalization had improved, and no contrast enhancement was observed. Brain MRI revealed a 1.5-cm contrast-enhanced mass in the left middle cranial fossa (Fig. 1C). Because these findings were atypical for NMOSD relapse, a craniotomy and biopsy were performed. A histopathological examination revealed pleomorphic foamy histiocytic cells with numerous mitotic figures and multinucleated giant cells (Fig. 1D). Immunohistochemistry was positive for CD68, CD163, and factor XIIIa, and negative for CD1a, S-100 protein, and epithelial membrane antigen (Fig. 1E and F). The BRAF V600E mutation was not detected. A subsequent CSF cytological examination of the sample obtained during the initial hospitalization revealed histiocyte-like cells with abundant clear cytoplasm. The findings of whole-body computed tomography and bone scintigraphy did not suggest any histiocyte proliferation, and hence PCNSHS was diagnosed. Chemotherapy with cladribine was initiated, but this did not improve the neurological condition of the patient. She developed cardiac dysfunction and sepsis 8 days after the initiation of chemotherapy, which prompted the discontinuation of chemotherapy and the transition to supportive care. The patient died approximately 2 weeks later. To the best of our knowledge, this is the first reported case of the co-occurrence of NMOSD and HS. The neurological symptoms were initially attributed to NMOSD based on serological and radiological findings, but the subsequent development of cauda equina enhancement and a CNS mass raised suspicion of an alternative or concurrent pathology. The histological diagnosis of HS highlights the importance of performing a tissue biopsy in such cases. While paraneoplastic NMOSD has been associated with malignancies such as breast, lung, and genitourinary cancers, there have been no prior reports involving HS.56 In contrast, there is a previous case report of PCNSHS with lesions meeting the diagnostic criteria for seronegative NMOSD.7 It is possible that the coexistence of these two rare conditions in the present case was coincidental. The presence of histiocyte-like cells in the initial CSF cytological examination suggests that the initial thoracic spinal cord lesion could have been indicative of HS. The aggressiveness of HS makes its early diagnosis critical, but this is particularly challenging when it mimics the relapse or progression of a known autoimmune disease. The present case underscores the importance of considering neoplastic processes—including rarer ones—in patients with NMOSD with new or atypical neurological features. This case highlights the importance of maintaining a high level of suspicion for underlying malignancies in patients with NMOSD presenting with atypical features or progression. Early comprehensive evaluations are essential for accurate diagnoses, and they may significantly affect the applied therapeutic strategies and also the prognoses, even in rare malignancies such as HS. The coexistence of NMOSD and HS is exceedingly rare, but this still highlights the diagnostic challenge of differentiating autoimmune relapse from the underlying malignancy. Careful monitoring and prompt histopathological assessment are essential for the accurate diagnosis and appropriate treatment of such complex cases.